Pulse Biosciences enrolls first 7 patients in NANOPULSE-AF pivotal trial for nPulse AFib catheter

PULSE BIOSCIENCES, INC.

First 7 patients treated at St. Bernards Medical Center by Devi Nair, MD.
Study plans to enroll ~215 participants across multiple sites; endpoints at 6 and 12 months.
Prior feasibility study showed 96% procedural success at 12 months and 100% acute success.
nPulse catheter uses nanosecond pulsed field ablation, integrated with Abbott EnSite X mapping.
Company aims to evaluate safety and efficacy for drug-resistant paroxysmal AF.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.